A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl-CCNU, in advanced sarcomas.
D000328:Adult; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003606:Dacarbazine / Q000627:therapeutic use*; D003609:Dactinomycin / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy; D006393:Hemangiopericytoma / Q000188:drug therapy; D018219:Histiocytoma, Benign Fibrous / Q000188:drug therapy; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy; D008130:Lomustine / Q000627:therapeutic use*; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy; D009455:Neurofibroma / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy*; D014226:Triazenes / Q000627:therapeutic use*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D009607:Nitrosourea Compounds; D014226:Triazenes; D003609:Dactinomycin; D014750:Vincristine; D008130:Lomustine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide